ResveratrolanimalAnimal model2021

Rational Design of Resveratrol O-methyltransferase for the Production of Pinostilbene.

International journal of molecular sciences

confidence

Key findings

Rational design of VvROMT variants to convert resveratrol to pinostilbene; no clinical or biological endpoints reported.

View source on PubMed (PMID 33919396) ↗

Sample size
Not applicable
Population
In vitro enzyme engineering study (Vitis vinifera O-methyltransferase)
Dosing
Not applicable
Duration
Not reported
Route
Not applicable
Blinding
not_reported
Controls
none
Drug class
polyphenol
Full abstract

Pinostilbene is a monomethyl ether analog of the well-known nutraceutical resveratrol. Both compounds have health-promoting properties, but the latter undergoes rapid metabolization and has low bioavailability. O-methylation improves the stability and bioavailability of resveratrol. In plants, these reactions are performed by O-methyltransferases (OMTs). Few efficient OMTs that monomethylate resveratrol to yield pinostilbene have been described so far. Here, we report the engineering of a resveratrol OMT from Vitis vinifera (VvROMT), which has the highest catalytic efficiency in di-methylating resveratrol to yield pterostilbene. In the absence of a crystal structure, we constructed a three-dimensional protein model of VvROMT and identified four critical binding site residues by applying different in silico approaches. We performed point mutations in these positions generating W20A, F24A, F311A, and F318A variants, which greatly reduced resveratrol's enzymatic conversion. Then, we rationally designed eight variants through comparison of the binding site residues with other stilbene OMTs. We successfully modified the native substrate selectivity of VvROMT. Variant L117F/F311W showed the highest conversion to pinostilbene, and variant L117F presented an overall increase in enzymatic activity. Our results suggest that VvROMT has potential for the tailor-made production of stilbenes.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.